Gastrointestinal Pathogen Testing Market Report 2025

This Gastrointestinal Pathogen Testing market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The gastrointestinal pathogen testing market size has grown steadily in recent years. It will grow from $4.05 billion in 2024 to $4.24 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to the increased prevalence of gastrointestinal infections, growth in awareness about foodborne illnesses, globalization leading to higher travel-related infections, regulatory initiatives for food safety, rise in healthcare expenditure, and heightened demand for rapid and accurate diagnostic solutions.

The gastrointestinal pathogen testing market size is expected to see steady growth in the next few years. It will grow to $5.01 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to the increasing prevalence of gastrointestinal infections globally, growing awareness about the importance of early detection and treatment, expanding healthcare infrastructure in emerging economies, rising demand for point-of-care testing solutions, heightened focus on food safety regulations, and continuous research and development efforts. Major trends in the forecast period include rapid testing methods, growing adoption of molecular diagnostic techniques, expansion of point-of-care testing in non-traditional healthcare settings, advancements in automation and robotics for streamlined testing processes, the emergence of novel biomarkers for enhanced pathogen detection, and integration of artificial intelligence and machine learning algorithms.

The increasing occurrences of foodborne illnesses are poised to drive the expansion of the gastrointestinal pathogen testing market in the foreseeable future. Foodborne diseases encompass illnesses resulting from the consumption of food or beverages contaminated with harmful microorganisms, toxins, or chemical substances, including ailments such as listeriosis, viral gastroenteritis, taeniasis, and trichinosis. The upsurge in foodborne incidents can be attributed to various factors such as shifts in food production, distribution, and consumption practices, inadequate food safety protocols, and the impacts of climate change on food production. Gastrointestinal testing plays a crucial role in identifying the specific pathogens responsible for foodborne illnesses, aiding healthcare providers in diagnosing gastrointestinal symptoms, determining suitable treatment approaches, monitoring outbreaks, and implementing preventive measures to mitigate the spread of foodborne diseases. For instance, data from the UK Health Security Agency in February 2024 revealed an increase in listeriosis cases in England and Wales, with 167 reported cases in 2022 compared to 160 cases in 2021, underscoring the growing significance of gastrointestinal pathogen testing.

Key players in the gastrointestinal pathogen testing market are directing their efforts towards developing cutting-edge solutions, such as metagenomic diagnostic tests, to enhance the precision, speed, and comprehensiveness of gastrointestinal pathogen detection. Metagenomic diagnostic tests represent advanced technologies utilized for analyzing the genetic material of microorganisms present in samples such as stool or blood. For example, Microba Life Sciences, an Australia-based biotechnology company, introduced MetaPanel in April 2024 - a metagenomic diagnostic test engineered to identify a broad spectrum of gastrointestinal pathogens with unprecedented accuracy. MetaPanel encompasses 175 pathogen targets within a single test, offering healthcare practitioners a comprehensive tool for diagnosing both common and challenging infections. Leveraging next-generation sequencing (NGS) technology, MetaPanel analyzes a diverse range of genetic material in stool samples, enabling the detection of various potential pathogens, including those not routinely assessed in traditional gastrointestinal panels.

In August 2022, SSI Diagnostica Group (SSID), a Denmark-based in-vitro diagnostics company, completed the acquisition of TechLab for an undisclosed sum. This acquisition is envisioned to broaden SSID's portfolio of infectious disease products and facilitate accelerated growth in the US market. The strategic move brings valuable commercial and manufacturing expertise, particularly in the pivotal US market. TechLab, based in the US, specializes in delivering rapid diagnostic tests for infectious diseases associated with the gastrointestinal and enteric systems.

Major companies operating in the gastrointestinal pathogen testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Becton Dickinson and Company, Hologic Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A., Cepheid Inc., OraSure Technologies Inc., BioFire Diagnostics Inc., Luminex Corporation, Meridian Bioscience Inc., Sekisui Diagnostics LLC, ELITechGroup S.A.S., Hardy Diagnostics LLC, Trinity Biotech plc, Puritan Medical Products Co. LLC, Cosmo Bio Co. Ltd., R-Biopharm AG, COPAN Diagnostics Inc., Savyon Diagnostics Ltd., ZeptoMetrix Corporation, Biomerica Inc., Pro-Lab Diagnostics.

North America was the largest region in the gastrointestinal pathogen testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal pathogen testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastrointestinal pathogen testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastrointestinal pathogen testing refers to the diagnostic process aimed at identifying infections and diseases resulting from various pathogens affecting the digestive tract, which includes the stomach and intestines. This involves analyzing specimens such as stool or blood to identify the specific pathogens responsible for gastrointestinal symptoms, enabling accurate diagnosis and treatment of gastrointestinal disorders.

The primary types of pathogens targeted in gastrointestinal pathogen testing include bacteria, viruses, and parasites, all of which can cause illness in the digestive system. Various testing methods are employed, including molecular tests, culture techniques, biochemical assays, and others, with different panel types available, such as syndromic full multiplex panels and others. These testing services cater to a range of end-users, including hospitals, diagnostic laboratories, point-of-care facilities, and others.

The gastrointestinal pathogen testing market research report is one of a series of new reports that provides gastrointestinal pathogen testing market statistics, including gastrointestinal pathogen testing industry global market size, regional shares, competitors with a gastrointestinal pathogen testing market share, detailed gastrointestinal pathogen testing market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal pathogen testing industry. This gastrointestinal pathogen testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastrointestinal pathogen testing market consists of revenues earned by entities by providing services, such as molecular testing, culture and sensitivity testing, and rapid diagnostics tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal pathogen testing market also includes sales of testing kits, laboratory equipment, and PCR (Polymerase Chain Reaction) machines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.